查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1413111

新抗原癌症疫苗市場：按產品、技術、遞送機制、新抗原類型、給藥途徑和應用 - 2024-2030 年全球預測

Neoantigen Cancer Vaccine Market by Product, Technology, Delivery Mechanism, Neoantigen Type, Route of Administration, Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年新抗原癌症疫苗市場規模為5,714萬美元，2024年將達6,044萬美元，2030年將達8,135萬美元，複合年成長率為5.17%。

新抗原癌症疫苗的全球市場

主要市場統計
基準年[2023] 5714萬美元
預測年份 [2024] 6044萬美元
預測年份 [2030] 8135萬美元
複合年成長率（%） 5.17%
新抗原癌症疫苗市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估新抗原癌症疫苗市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對新抗原癌症疫苗市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-新抗原癌症疫苗市場的市場規模和預測是多少？

2-新抗原癌症疫苗市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3-新抗原癌症疫苗市場的技術趨勢和法律規範是什麼？

4-新抗原癌症疫苗市場主要供應商的市場佔有率是多少？

5-進入新抗原癌症疫苗市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症盛行率上升
      • 改善基因組序列測定和免疫治療
      • 癌症早期診斷和治療的趨勢
    • 抑制因素
      • 高製造成本和複雜性
    • 機會
      • 持續研發以提高新抗原癌症疫苗的功效
      • 聯合治療的新進展
    • 任務
      • 副作用和倫理問題
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章新抗原癌症疫苗市場：依產品

  • 市售新抗原疫苗
  • 個體化新抗原疫苗

第7章新抗原癌症疫苗市場：依技術分類

  • HLA分型
  • RNA定序
  • 全基因組序列測定

第8章新抗原癌症疫苗市場依輸送機制分類

  • 電穿孔
  • 吉恩·岡恩
  • 脂質體
  • 病毒體

第9章新抗原癌症疫苗市場（以新抗原類型）

  • 樹突狀細胞
  • 核酸
  • 合成長勝胜肽
  • 癌細胞

第10章新抗原癌症疫苗市場：依給藥途徑

  • 肌肉注射
  • 靜脈
  • 經皮

第11章新抗原癌症疫苗市場：依應用分類

  • 腦腫瘤
  • 消化道癌症
  • 肺癌
  • 黑色素瘤

第12章美洲新抗原癌症疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太地區新抗原癌症疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲新抗原癌症疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：按主要企業分類
  • 主要企業競爭情境分析

第16章競爭組合

  • 主要公司簡介
    • "
    • "Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
    • Advaxis Inc.
    • Agenus Inc.
    • AstraZeneca plc
    • Avidea Technologies
    • BioLineRx
    • BioNTech SE
    • Brightpath Biotherapeutics Co., Ltd.
    • CureVac NV
    • Elicio Therapeutics Inc
    • F. Hoffmann-La Roche Ltd.
    • Genocea Biosciences Inc
    • Gilead Sciences, Inc.
    • Gritstone bio, Inc.
    • Immunomic Therapeutics, Inc.
    • IMV Inc
    • ISA Pharmaceuticals BV
    • Medigene AG
    • Merck & Co., Inc.
    • Neophore Limited
    • Nouscom
    • Nykode Therapeutics ASA
    • OSE Immunotherapeutics
    • Takis srl
  • 主要產品系列

第17章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-5C6F41F5B004

[190 Pages Report] The Neoantigen Cancer Vaccine Market size was estimated at USD 57.14 million in 2023 and expected to reach USD 60.44 million in 2024, at a CAGR 5.17% to reach USD 81.35 million by 2030.

Global Neoantigen Cancer Vaccine Market

KEY MARKET STATISTICS
Base Year [2023] USD 57.14 million
Estimated Year [2024] USD 60.44 million
Forecast Year [2030] USD 81.35 million
CAGR (%) 5.17%
Neoantigen Cancer Vaccine Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Neoantigen Cancer Vaccine Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Neoantigen Cancer Vaccine Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Neoantigen Cancer Vaccine Market, highlighting leading vendors and their innovative profiles. These include ", "Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc., Advaxis Inc., Agenus Inc., AstraZeneca plc, Avidea Technologies, BioLineRx, BioNTech SE, Brightpath Biotherapeutics Co., Ltd., CureVac N.V., Elicio Therapeutics Inc, F. Hoffmann-La Roche Ltd., Genocea Biosciences Inc, Gilead Sciences, Inc., Gritstone bio, Inc., Immunomic Therapeutics, Inc., IMV Inc, ISA Pharmaceuticals BV, Medigene AG, Merck & Co., Inc., Neophore Limited, Nouscom, Nykode Therapeutics ASA, OSE Immunotherapeutics, and Takis srl.

Market Segmentation & Coverage

This research report categorizes the Neoantigen Cancer Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Off-The Shell Neoantigen Vaccine
    • Personalized Neo-Antigen Vaccine
  • Technology
    • HLA Typing
    • RNA Sequencing
    • Whole Genome Sequencing
  • Delivery Mechanism
    • Electroporation
    • Gene Gun
    • Liposomes
    • Virosomes
  • Neoantigen Type
    • Dendritic Cell
    • Nucleic Acid
    • Synthetic Long Peptide
    • Tumor Cell
  • Route of Administration
    • Intramuscular
    • Intravenous
    • Transdermal
  • Application
    • Brain Cancer
    • Gastrointestinal Cancer
    • Lung Cancer
    • Melanoma
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Neoantigen Cancer Vaccine Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Neoantigen Cancer Vaccine Market?

3. What are the technology trends and regulatory frameworks in the Neoantigen Cancer Vaccine Market?

4. What is the market share of the leading vendors in the Neoantigen Cancer Vaccine Market?

5. Which modes and strategic moves are suitable for entering the Neoantigen Cancer Vaccine Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Neoantigen Cancer Vaccine Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer globally
      • 5.1.1.2. Improvements in genomic sequencing and immunotherapy
      • 5.1.1.3. Inclination towards early diagnosis and treatment of cancer
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and complexity in manufacturing
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D to improve efficacy of neoantigen cancer vaccine
      • 5.1.3.2. Emerging development of combination therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects and ethical issues
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Neoantigen Cancer Vaccine Market, by Product

  • 6.1. Introduction
  • 6.2. Off-The Shell Neoantigen Vaccine
  • 6.3. Personalized Neo-Antigen Vaccine

7. Neoantigen Cancer Vaccine Market, by Technology

  • 7.1. Introduction
  • 7.2. HLA Typing
  • 7.3. RNA Sequencing
  • 7.4. Whole Genome Sequencing

8. Neoantigen Cancer Vaccine Market, by Delivery Mechanism

  • 8.1. Introduction
  • 8.2. Electroporation
  • 8.3. Gene Gun
  • 8.4. Liposomes
  • 8.5. Virosomes

9. Neoantigen Cancer Vaccine Market, by Neoantigen Type

  • 9.1. Introduction
  • 9.2. Dendritic Cell
  • 9.3. Nucleic Acid
  • 9.4. Synthetic Long Peptide
  • 9.5. Tumor Cell

10. Neoantigen Cancer Vaccine Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Intramuscular
  • 10.3. Intravenous
  • 10.4. Transdermal

11. Neoantigen Cancer Vaccine Market, by Application

  • 11.1. Introduction
  • 11.2. Brain Cancer
  • 11.3. Gastrointestinal Cancer
  • 11.4. Lung Cancer
  • 11.5. Melanoma

12. Americas Neoantigen Cancer Vaccine Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Neoantigen Cancer Vaccine Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Neoantigen Cancer Vaccine Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. FPNV Positioning Matrix
  • 15.2. Market Share Analysis, By Key Player
  • 15.3. Competitive Scenario Analysis, By Key Player

16. Competitive Portfolio

  • 16.1. Key Company Profiles
    • 16.1.1. "
    • 16.1.2. "Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
    • 16.1.3. Advaxis Inc.
    • 16.1.4. Agenus Inc.
    • 16.1.5. AstraZeneca plc
    • 16.1.6. Avidea Technologies
    • 16.1.7. BioLineRx
    • 16.1.8. BioNTech SE
    • 16.1.9. Brightpath Biotherapeutics Co., Ltd.
    • 16.1.10. CureVac N.V.
    • 16.1.11. Elicio Therapeutics Inc
    • 16.1.12. F. Hoffmann-La Roche Ltd.
    • 16.1.13. Genocea Biosciences Inc
    • 16.1.14. Gilead Sciences, Inc.
    • 16.1.15. Gritstone bio, Inc.
    • 16.1.16. Immunomic Therapeutics, Inc.
    • 16.1.17. IMV Inc
    • 16.1.18. ISA Pharmaceuticals BV
    • 16.1.19. Medigene AG
    • 16.1.20. Merck & Co., Inc.
    • 16.1.21. Neophore Limited
    • 16.1.22. Nouscom
    • 16.1.23. Nykode Therapeutics ASA
    • 16.1.24. OSE Immunotherapeutics
    • 16.1.25. Takis srl
  • 16.2. Key Product Portfolio

17. Appendix

  • 17.1. Discussion Guide
  • 17.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. NEOANTIGEN CANCER VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. NEOANTIGEN CANCER VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. NEOANTIGEN CANCER VACCINE MARKET DYNAMICS
  • FIGURE 7. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2023 VS 2030 (%)
  • FIGURE 12. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2023 VS 2030 (%)
  • FIGURE 14. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 16. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 18. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 22. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 27. NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 28. NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. NEOANTIGEN CANCER VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY OFF-THE SHELL NEOANTIGEN VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEO-ANTIGEN VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 9. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 13. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GENE GUN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VIROSOMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NUCLEIC ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC LONG PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY BRAIN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GASTROINTESTINAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 282. NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 283. NEOANTIGEN CANCER VACCINE MARKET LICENSE & PRICING